Cargando…

Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment

OBJECTIVE: The objective of the study was to assess the tolerability and safety of galcanezumab in patients with chronic cluster headache (CH) with up to 15 months of treatment. BACKGROUND: Chronic CH is a highly debilitating disease with a substantial and unmet medical need. METHODS: Patients were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Láinez, Miguel J. A., Schoenen, Jean, Stroud, Chad, Bardos, Jennifer, Bangs, Mark, Kemmer, Phebe, Wenzel, Richard, Kuruppu, Dulanji K., Martinez, James Michael, Oakes, Tina M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Submissions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299588/ https://www.ncbi.nlm.nih.gov/pubmed/34806783 http://dx.doi.org/10.1111/head.14234

Ejemplares similares

Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache
por: Kudrow, David, et al.
Publicado: (2020)

Does “wearing off” of efficacy occur in galcanezumab‐treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials
por: Ailani, Jessica, et al.
Publicado: (2022)

Impact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache
por: Andrews, J Scott, et al.
Publicado: (2021)

Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment
por: Fofi, Luisa, et al.
Publicado: (2022)

Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies
por: Detke, Holland C., et al.
Publicado: (2019)

Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine
por: Ford, Janet H., et al.
Publicado: (2020)

A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene‐related peptide ligand (galcanezumab) or receptor (erenumab) antagonist
por: Kudrow, David, et al.
Publicado: (2022)

Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials
por: Stauffer, Virginia L., et al.
Publicado: (2019)

Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
por: Bangs, Mark E., et al.
Publicado: (2020)

Reducing Episodic Cluster Headaches: Focus on Galcanezumab
por: Pellesi, Lanfranco, et al.
Publicado: (2020)

Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine
por: Popoff, Evan, et al.
Publicado: (2021)

Correction to: Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies
por: Bangs, Mark E., et al.
Publicado: (2020)

Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures
por: Schwedt, Todd J., et al.
Publicado: (2021)

Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment
por: Dodick, David W, et al.
Publicado: (2020)

Galcanezumab for migraine
Publicado: (2020)

Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments
por: Kuruppu, Dulanji K., et al.
Publicado: (2021)

Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE‐1, EVOLVE‐2, and REGAIN Randomized, Double‐Blind, Placebo‐Controlled Studies
por: Nichols, Russell, et al.
Publicado: (2018)

100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 Studies
por: Rosen, Noah, et al.
Publicado: (2018)

Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials
por: Kuruppu, Dulanji K., et al.
Publicado: (2021)

Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache
por: Mo, Heejung, et al.
Publicado: (2022)

Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double‐Blind, Placebo‐Controlled REGAIN, and Pooled EVOLVE‐1 and EVOLVE‐2 Studies
por: Smitherman, Todd A., et al.
Publicado: (2020)

Galcanezumab-induced fixed drug eruption
por: Klager, Skylar, et al.
Publicado: (2021)

Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients with Migraine: Three Cases
por: Kashiwagi, Kenta, et al.
Publicado: (2023)

An Evidence-Based Review of Galcanezumab for the Treatment of Migraine
por: Urits, Ivan, et al.
Publicado: (2020)

Photophobia and migraine outcome during treatment with galcanezumab
por: Schiano di Cola, Francesca, et al.
Publicado: (2023)

Galcanezumab-Induced Myasthenia Gravis-Like Symptoms
por: Mubaraki, Adnan A
Publicado: (2023)

Preventive therapy with galcanezumab for two consecutive cluster bouts in patients with episodic cluster headache: an observational multicenter study
por: Hong, Yooha, et al.
Publicado: (2023)

Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials
por: Stauffer, Virginia L., et al.
Publicado: (2020)

One-Time Use of Galcanezumab or Fremanezumab for Migraine Prevention
por: Katsuki, Masahito, et al.
Publicado: (2023)

Galcanezumab modulates Capsaicin-induced C-fiber reactivity
por: Basedau, Hauke, et al.
Publicado: (2022)

Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis
por: Goadsby, Peter J, et al.
Publicado: (2019)

Chronobiology and Sleep in Cluster Headache
por: de Coo, Ilse F., et al.
Publicado: (2019)

Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials
por: Yang, Yanbo, et al.
Publicado: (2020)

The Neuropsychology of Cluster Headache: Cognition, Mood, Disability, and Quality of Life of Patients With Chronic and Episodic Cluster Headache
por: Torkamani, Mariam, et al.
Publicado: (2015)

The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions
por: Gklinos, Panagiotis, et al.
Publicado: (2021)

Real-life experiences with galcanezumab and predictors for treatment response in Turkey
por: Yalinay Dikmen, Pınar, et al.
Publicado: (2023)

Effectiveness of Oxygen and Other Acute Treatments for Cluster Headache: Results From the Cluster Headache Questionnaire, an International Survey
por: Pearson, Stuart M., et al.
Publicado: (2019)

Cluster headache is one of the most intensely painful human conditions: Results from the International Cluster Headache Questionnaire
por: Burish, Mark J., et al.
Publicado: (2020)

Challenges and complexities in designing cluster headache prevention clinical trials: A narrative review
por: Dodick, David W., et al.
Publicado: (2022)

Efficacy of galcanezumab in patients with migraine and history of failure to 3–4 preventive medication categories: subgroup analysis from CONQUER study
por: Okonkwo, Rose, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_28bvretlv2uh0c5s25bqvs3uvg